drugset / Trial / NCT06430112

Liposomal Bupivacaine vs Ropivacaine for TAPBs

NCT06430112

Phase 3 Unknown 74 enrolled Sun Yat-sen University
RandomizedParallel-groupSingle-blindTreatment

Summary

Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.

Timeline

Start
2023-11-01
Primary completion
2024-05-20
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other
Comparator Ropivacaine Other / unclassified 0.25 % Other
Comparator Ropivacaine Other / unclassified 40 ml Other

Indications

No indication recorded.